News
NIH’s Steven Ferguson will be speaking at the Licensing Executives Society (LES) upcoming virtual seminar titled Industry, Universities, and Government – How to Work Together Through Contracts. This seminar will take place on June 25, 2024 from 10am-1pm EST. “The interface between institutions doing
A monoclonal antibody therapy discovery that arose from a 2005 research collaboration between scientists at the National Cancer Institute (NCI) and the Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) has again been designated for human compassionate therapeutic use – this
Each year NIH Technology Transfer releases a list of the top 20 royalty-on-sales grossing products of the year based upon license agreements to inventions made by the NIH intramural research program. The list is broken down into four categories: vaccines and therapeutics, diagnostics
A novel anti-cancer therapy to target the Proviral Integration of the Moloney murine leukemia virus (PIM) kinases is available for licensing and co-development. PIM kinases are overexpressed in many solid cancers, which is predictive of poor survival in multiple cancer types. NIH inventors have